Chinese PE firm TMCP invested $2.4 million in US firm RNAimmune

Chinese private equity firm Terra Magnum Capital Partners has invested $2.35 million in US-based RNAimmune

Founded in 2016, Terra Magnum Capital Partners (TMCP) has over $800 million assets under management and specializes in both direct investments and fund investments. It has offices in Beijing, Shanghai and United States. Sha Wang, Ben Wang, Ray Yang, Frank Qin, Ming Liu and Justin Chang are among their partners and directors. (RNAimmune is a biopharmaceutical company in Gaithersburg with more than 20 years of experience in cancer therapies, antibody therapies and treatment of rare diseases)

Terra Magnum Capital Partners is listed in the Chinese Investors Directory with the code SJ78